Effects of pioglitazone and metformin on mitochondrial function evaluated with 31P MRS in type 2 DM.

Effects of pioglitazone and metformin on mitochondrial function evaluated with 31P MRS in type 2 DM. - 31P MRS measurement of mitochondrial function and insulin resistance. (3M study)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000814

Enrollment

Registered

2007-10-01

Start date

2007-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

pioglitazone (15-30mg/day) metformin (750mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes mellitus Japanese patients not used either thiazolidinediones nor biguanide.

Exclusion criteria

Exclusion criteria: 1. Severe renal dysfunction(serum creatinine>2.0mg/dl) 2. Severe liver dysfunction(AST, ALT>50IU/ml) 3. Severe heart failure 4. History of hypersensitivity to pioglitazone or metformin 5. During the pregnancy or nursing 6. Arteriosclerosis obliterans (ASO) (ABI<0.9) 7. Poor control of plasma glucose (FPG>150mg/dl) 8. Inadequate to entry to this study

Design outcomes

Primary

Measure	Time frame
Measurement of mitochondrial function of skeletal muscle before and after 24 weeks treatment with different insulin sensitizers.	—

Secondary

Measure	Time frame
1. Measurement of the amount of visceral fat, IMCL and HLC before and after 24 weeks treatment. 2. Measurement of GIR before and after 24 weeks treatment. 3. Measurement of FPG, IRI, HbA1c, total-cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, FFA, adipocytokines before and after 24 weeks treatment. 4. Measurement of body weight and waist before and after 24 weeks treatment.	—

Countries

Japan

Contacts

Public ContactKazuhiko Sakaguchi

Kobe University Graduate School of Medicine Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine

kzhkskgc@med.kobe-u.ac.jp078-382-5861

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026